Covid-19 man­u­fac­tur­ing roundup: NY biotech primed to be­come Im­mu­ni­ty­Bio's drug sub­stance gold­mine; Illi­nois set to meet de­mand for at-home tests

A Buf­fa­lo, NY drug man­u­fac­tur­ing site that was fund­ed with $200 mil­lion of state mon­ey could soon be­come Im­mu­ni­ty­Bio’s largest man­u­fac­tur­er of Covid-19 vac­cine drug sub­stance by the end of the year.

The Cal­i­for­nia biotech agreed to take over the lease from Athenex, a Buf­fa­lo bio­phar­ma. The site ran in­to a num­ber of cost­ly reg­u­la­to­ry set­backs that de­layed op­er­a­tions.

“We have great am­bi­tions to make this plant our star plant, and re­al­ly the idea is to build a cam­pus around the plant and ac­tu­al­ly bring New York as our bi­o­log­i­cal man­u­fac­tur­ing hub,” ex­ec­u­tive chair­man Patrick Soon-Sh­iong told The Buf­fa­lo News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER